Feature Papers in the Section “Cancer Therapy” in 2025
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 89
Special Issue Editors
2. Houston Methodist Research Institute, Houston, TX 77030, USA
Interests: transplant oncology; liver cancer; cholangiocarcinoma; targeted therapy; immunotherapy
Special Issues, Collections and Topics in MDPI journals
2. Dr. Mary and Ron Neal Cancer Center, Houston Methodist, Houston, TX 77030, USA
Interests: cancer biology; solid cancers; hem-oncology; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Interests: breast cancer; endocrine therapy; chemotherapy; surgical therapy; tumor angiogenesis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This collection is the second edition of the Special Issue “Feature Paper in Section “Cancer Therapy” in 2024” (https://www.mdpi.com/journal/cancers/special_issues/851NXE23AN).
As a result of the development and improvement of modalities for systematic and localized treatment, the field of oncology has undergone a complete revolution. To effectively manage the progression of cancer, it is essential to have therapeutic approaches that are both precise and targeted, as well as those that are particular to the affected area and may be utilized at an early stage. The major method that is utilized for people who are qualified to undergo surgical removal of their tumor is one of these. Chemotherapy is a medication that is frequently used in the treatment of cancer, yet it is notorious for the significant toxicity that it causes in patients. On the other hand, as a pharmaceutical intervention, it is currently being utilized in conjunction with immunotherapy increasingly frequently. The effectiveness of immunotherapy is based on its capacity to strengthen the immune system of the host, which makes it an appropriate supplement to the standard of care that has been established for long-term treatment. In addition, immunotherapy has undergone substantial changes, particularly since the Food and Drug Administration (FDA) authorized it for the treatment of more advanced cancers. Additionally, the increasing validity and effectiveness of immunotherapies have been demonstrated in recent clinical research trials, which have been conducted all over the world with the purpose of improving oncology treatments. To improve both survival rates and quality of life in the field of cancer, it is essential to continue developing each of these therapy techniques. This Special Issue will discuss the innovations recently made in chemo- and immunotherapy and other developments and specializations in the field, such as targeted therapy.
Dr. Abdullah Esmail
Dr. Qiang Wang
Prof. Dr. Hiroyuki Takei
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chemotherapy
- immunotherapy for cancer
- oncology
- systemic treatment and targeted therapy.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
